pembrolizumab
merck
['keynote-412', 'head and neck', 'merck']
in a late-stage phase iii keynote-412 trial for unresected locally advanced head and neck squamous cell carcinoma, 's pd-1 inhibitor failed to meet its primary endpoint. get more detailed insights: #esmo2022 #esmo #esmo22 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry